FDA approves Ceptaris' Valchlor gel for cutaneous T-cell lymphoma

08/26/2013 | Pharmaceutical Business Review Online

The FDA has granted Ceptaris Therapeutics approval to market its Valchlor gel for treatment of patients with stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma who previously received skin-directed treatment. The approval makes Valchlor gel the only FDA-cleared formulation of mechlorethamine, or nitrogen mustard.

View Full Article in:

Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Medical Device Reimbursement Specialist - Regional
Alcon
Fort Worth , TX
Assistant General Counsel/Senior Corporate Counsel - Healthcare Law Group
Genentech
94080, CA
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX